ICU Medical (NASDAQ:ICUI) VP Sells $819,158.64 in Stock

ICU Medical, Inc. (NASDAQ:ICUI) VP Virginia Sanzone sold 4,856 shares of ICU Medical stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $168.69, for a total value of $819,158.64. Following the transaction, the vice president owned 14,604 shares in the company, valued at approximately $2,463,548.76. This represents a 24.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ICU Medical Trading Up 0.8%

NASDAQ ICUI opened at $167.58 on Friday. The firm has a market cap of $4.19 billion, a P/E ratio of 142.02, a P/E/G ratio of 2.12 and a beta of 0.75. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. The stock’s 50-day moving average is $167.35 and its 200-day moving average is $144.86. ICU Medical, Inc. has a one year low of $112.50 and a one year high of $192.85.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.46. The business had revenue of $547.88 million during the quarter, compared to analysts’ expectations of $533.44 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.ICU Medical’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the prior year, the business earned $2.10 EPS. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Sell-side analysts anticipate that ICU Medical, Inc. will post 7.19 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on ICUI. Weiss Ratings raised ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. Sanford C. Bernstein cut ICU Medical to a “market perform” rating in a research note on Monday, June 15th. KeyCorp upped their price target on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 21st. Zacks Research cut shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Finally, Piper Sandler lifted their price objective on shares of ICU Medical from $163.00 to $195.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, ICU Medical presently has an average rating of “Moderate Buy” and a consensus target price of $192.80.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Allworth Financial LP acquired a new position in shares of ICU Medical during the 2nd quarter worth approximately $26,000. Hilton Head Capital Partners LLC acquired a new stake in shares of ICU Medical in the 4th quarter valued at approximately $32,000. Public Employees Retirement System of Ohio bought a new position in shares of ICU Medical in the second quarter valued at $51,000. Covestor Ltd grew its stake in shares of ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock valued at $99,000 after buying an additional 126 shares in the last quarter. Finally, Strs Ohio increased its holdings in ICU Medical by 60.0% during the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after buying an additional 300 shares during the last quarter. 96.10% of the stock is owned by institutional investors and hedge funds.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.